Wiebke Albrecht
Overview
Explore the profile of Wiebke Albrecht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albrecht W, Brecklinghaus T, Stolte M, Kappenberg F, Grundler L, Chen P, et al.
ALTEX
. 2025 Feb;
PMID: 39955620
Prediction of hepatotoxicity in humans remains an unresolved challenge. Recently, an in-vitro/in-silico-method was established to predict blood concentrations of test compounds with an increased risk of causing human hepatotoxicity. In...
2.
Schurmeyer L, Peng C, Albrecht W, Brecklinghaus T, Baur P, Hengstler J, et al.
Arch Toxicol
. 2024 Nov;
99(1):357-376.
PMID: 39547999
Concentration-dependent cytotoxicity experiments are frequently used in toxicology. Although it has been reported that an adequate choice of concentrations improves the quality of the statistical inference substantially, a recent literature...
3.
Adhikari S, Wang Y, Spaeth P, Scalerandi F, Albrecht W, Liu J, et al.
Nano Lett
. 2024 Jul;
24(32):9861-9867.
PMID: 39078741
Magnetic nanomaterials record information as fast as picoseconds in computer memories but retain it for millions of years in ancient rocks. This exceedingly broad range of times is covered by...
4.
Kwon Y, Gottmann P, Wang S, Tissink J, Motzler K, Sekar R, et al.
J Hepatol
. 2024 Jul;
82(1):18-27.
PMID: 38977136
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Owing to limited available treatment options, novel pre-clinical models for target selection...
5.
Hassan R, Gerdemann A, Cramer B, Hobloss Z, Myllys M, Gonzalez D, et al.
Arch Toxicol
. 2024 Mar;
98(4):1081-1093.
PMID: 38436695
Large interspecies differences between rats and mice concerning the hepatotoxicity and carcinogenicity of aflatoxin B (AFB) are known, with mice being more resistant. However, a comprehensive interspecies comparison including subcellular...
6.
Xie X, Albrecht W, van Huis M, van Blaaderen A
Nanoscale
. 2024 Feb;
16(9):4787-4795.
PMID: 38305037
The shape of Au nanoparticles (NPs) plays a crucial role for applications in, amongst others, catalysis, electronic devices, biomedicine, and sensing. Typically, the deformation of the morphology of Au NPs...
7.
Ni B, Mychinko M, Gomez-Grana S, Morales-Vidal J, Obelleiro-Liz M, Heyvaert W, et al.
Adv Mater
. 2023 Dec;
36(4):e2312066.
PMID: 38161223
No abstract available.
8.
Ghallab A, Gonzalez D, Strangberg E, Hofmann U, Myllys M, Hassan R, et al.
J Hepatol
. 2023 Nov;
80(2):268-281.
PMID: 37939855
Background & Aims: Cholemic nephropathy (CN) is a severe complication of cholestatic liver diseases for which there is no specific treatment. We revisited its pathophysiology with the aim of identifying...
9.
Gerdemann A, Cramer B, Degen G, Veerkamp J, Gunther G, Albrecht W, et al.
Arch Toxicol
. 2023 Oct;
97(12):3179-3196.
PMID: 37794256
Aflatoxin B (AFB) is a highly hepatotoxic and carcinogenic mycotoxin produced by Aspergillus species. The compound is mainly metabolized in the liver and its metabolism varies between species. The present...
10.
Vucur M, Ghallab A, Schneider A, Adili A, Cheng M, Castoldi M, et al.
Immunity
. 2023 Jun;
56(7):1578-1595.e8.
PMID: 37329888
It is currently not well known how necroptosis and necroptosis responses manifest in vivo. Here, we uncovered a molecular switch facilitating reprogramming between two alternative modes of necroptosis signaling in...